Hanmi Pharm registers International Nonproprietary Name for its new immune disorder treatment
Hanmi Pharm(CEO Gwan-Sun Lee) decided a name of the self-developed new drug ‘HM71224’ for the treatment of immune system disorder on ‘Poseltinib.’
Hanmi Pharm announced on the 7th ‘Poseltinib’ was recently registered as the International Nonproprietary Name(INN), an official name given by the Wo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
